{"id":383381,"date":"2020-11-17T15:58:24","date_gmt":"2020-11-17T20:58:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383381"},"modified":"2020-11-17T15:58:24","modified_gmt":"2020-11-17T20:58:24","slug":"rm-law-announces-investigation-of-akers-biosciences-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/","title":{"rendered":"RM LAW Announces Investigation of Akers Biosciences, Inc."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n BERWYN, Pa.<\/span>, Nov. 17, 2020<\/span> \/PRNewswire\/ — RM LAW, P.C.<\/a> is investigating potential claims against the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers’ agreement to merge with MYMD Pharmaceuticals, Inc. (“MYMD”).<\/p>\n

\n

\n
\n \"\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

If you own shares of Akers Biosciences and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire<\/span> toll-free at (844) 291-9299 or to sign up online, click here<\/a>.\u00a0 You may also email Mr. Maniskas at rm@maniskas.com<\/a>. \u00a0<\/p>\n

Under the terms of the agreement, Akers will issue a number of shares of Akers common stock to MYMD’s shareholders. Upon completion of the merger, Akers’ shareholders will own approximately 20% of the combined company and MYMD’s shareholders will own approximately 80% of the combined company.<\/p>\n

RM LAW, P.C. is a national shareholder litigation firm.\u00a0 RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.\u00a0 To learn more about the class action process, please click here<\/a>.\u00a0 <\/p>\n

\n\n\n\n\n\n\n\n\n
\n

\n
\n CONTACT:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n RM LAW, P.C.<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Richard A. Maniskas, Esquire<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n 1055 Westlakes Dr., Ste. 300<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n Berwyn, PA 19312<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n \u00a0484-324-6800<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n 844-291-9299<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n
\n rm@maniskas.com<\/b>
\n <\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/rm-law-announces-investigation-of-akers-biosciences-inc-301175262.html<\/a><\/p>\n

SOURCE RM LAW, P.C.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BERWYN, Pa., Nov. 17, 2020 \/PRNewswire\/ — RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers’ agreement to merge with MYMD Pharmaceuticals, Inc. (“MYMD”). If you own shares of Akers Biosciences and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.\u00a0 You may also email Mr. Maniskas at rm@maniskas.com. \u00a0 Under the terms of the agreement, Akers … <\/p>\n

Continue reading “RM LAW Announces Investigation of Akers Biosciences, Inc.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383381","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BERWYN, Pa., Nov. 17, 2020 \/PRNewswire\/ — RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers’ agreement to merge with MYMD Pharmaceuticals, Inc. (“MYMD”). If you own shares of Akers Biosciences and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.\u00a0 You may also email Mr. Maniskas at rm@maniskas.com. \u00a0 Under the terms of the agreement, Akers … Continue reading "RM LAW Announces Investigation of Akers Biosciences, Inc."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T20:58:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RM LAW Announces Investigation of Akers Biosciences, Inc.\",\"datePublished\":\"2020-11-17T20:58:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/\"},\"wordCount\":248,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/\",\"name\":\"RM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"datePublished\":\"2020-11-17T20:58:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-akers-biosciences-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RM LAW Announces Investigation of Akers Biosciences, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/","og_locale":"en_US","og_type":"article","og_title":"RM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk","og_description":"PR Newswire BERWYN, Pa., Nov. 17, 2020 \/PRNewswire\/ — RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers’ agreement to merge with MYMD Pharmaceuticals, Inc. (“MYMD”). If you own shares of Akers Biosciences and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.\u00a0 You may also email Mr. Maniskas at rm@maniskas.com. \u00a0 Under the terms of the agreement, Akers … Continue reading \"RM LAW Announces Investigation of Akers Biosciences, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T20:58:24+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RM LAW Announces Investigation of Akers Biosciences, Inc.","datePublished":"2020-11-17T20:58:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/"},"wordCount":248,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/","name":"RM LAW Announces Investigation of Akers Biosciences, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","datePublished":"2020-11-17T20:58:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-akers-biosciences-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RM LAW Announces Investigation of Akers Biosciences, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383381"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383381\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}